【摘要】：近年來,肝病已越來越成為當(dāng)今威脅人類健康的主要疾病之一,病毒性肝炎中尤以乙型肝炎對人類影響最大,乙型肝炎病毒(HBV)感染是一個嚴(yán)重的全球性公共健康問題,成為了當(dāng)前的一種世界性疾病。 由于乙肝影響范圍的廣泛性,危害的嚴(yán)重性,乙型肝炎診斷試劑作為專用于乙肝患者各種生理指標(biāo)的檢測、乙肝的診斷和治療過程監(jiān)測的生物學(xué)和化學(xué)試劑,具有廣泛的應(yīng)用范圍和社會需求。 本研究就是在以前研究的基礎(chǔ)上,開發(fā)出針對乙肝e抗原的抗體。E抗原全長159個氨基酸,對它的抗原決定簇的性質(zhì)的研究也已經(jīng)有30多年的歷史,目前比較公認(rèn)的是它有三個主要抗原決定簇,兩個線性的,一個構(gòu)型的,其中一個主要線性抗原決定簇是HBeβ,定位在120-133氨基酸上,這是一個優(yōu)勢抗原決定簇。由于這個優(yōu)勢決定簇的存在,傳統(tǒng)的免疫方法只能獲得針對它的抗體。本研究采用改變常規(guī)的免疫方法而采用封閉優(yōu)勢決定簇的策略期望獲得針對非主要抗原決定簇的抗體,封閉的方法是用目前已經(jīng)獲得的針對這個主要決定簇的抗體和抗原共免疫。 通過免疫方法的改變,最后得到了兩個單克隆抗體-S-29-3和S-72-3。對它們的結(jié)合表位研究表明,S-29-3識別的表位是一個包含HBeβ這段序列在內(nèi)的構(gòu)型表位;S-72-3識別的是一個包含了一個很長序列氨基酸(2-118)的構(gòu)型表位。Biosensor親和力檢測顯示他們都具有很高的親和常數(shù),用它們代替進(jìn)口產(chǎn)品進(jìn)行配對檢測重組抗原,具有和商品化的配對抗體lpa相似的靈敏度。
[Abstract]:In recent years, liver disease has become one of the main diseases threatening human health more and more, especially hepatitis B has the greatest impact on human beings. Hepatitis B virus (HBV) infection is a serious global public health problem. It has become a worldwide disease. Because of the extensive scope of hepatitis B infection and the severity of the harm, hepatitis B diagnostic reagent is used as a biological and chemical reagent for the detection of various physiological indexes of hepatitis B patients, the diagnosis and treatment of hepatitis B, With a wide range of applications and social needs. On the basis of previous studies, we have developed antibodies against hepatitis B e antigen. The whole length of E antigen is 159 amino acids, and the properties of its antigenic determinants have been studied for more than 30 years. It is generally recognized that it has three main antigenic determinants, two linear and one configuration, one of which is HBe 尾, which is located on 120x133 amino acids, which is a dominant antigenic determinant. Because of the existence of this dominant determinant, traditional immune methods can only obtain antibodies against it. In this study, we used the strategy of blocking dominant determinants to obtain antibodies against non-major antigenic determinants by changing the conventional immune methods and using the strategy of blocking dominant determinants. The blocking method is to co-immunize with antibodies and antigens that are currently available against this major determinant. Through the change of immune method, two monoclonal antibodies-Sx293 and SJ72m3 were obtained. The results were as follows: (1). The study of their binding epitopes showed that the epitope recognized by Sx293 was a configuration epitope containing the sequence of HBe 尾. The biosensor affinity test shows that they all have a high affinity constant, so they are used to pair the recombinant antigen instead of the imported product, and the biosensor affinity test shows that they all have high affinity constant, and that the recombinant antigen contains a long sequence of amino acids (2 渭 118), and the biosensor affinity test shows that they all have very high affinity constants. It has a sensitivity similar to that of commercial pairing antibody lpa.
【學(xué)位授予單位】：中國科學(xué)院研究生院（上海生命科學(xué)研究院）
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2006
【分類號】：R392

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 彭仕芳;傅蕾;;胸腺素α_1治療慢性重型乙型病毒性肝炎的療效觀察[J];中國感染控制雜志;2007年04期

2 成軍,李莉;胸腺素α1在慢性病毒性肝炎治療中的應(yīng)用[J];國外醫(yī)學(xué).病毒學(xué)分冊;2001年02期

3 徐峰;胸腺素α1的作用機(jī)制及臨床應(yīng)用現(xiàn)況[J];國外醫(yī)學(xué).流行病學(xué)傳染病學(xué)分冊;2000年04期

4 鄧永岳,陳紫榕;聯(lián)合用藥治療慢性乙、丙型肝炎[J];國外醫(yī)學(xué).流行病學(xué)傳染病學(xué)分冊;2004年03期

5 梁峗磊;成軍;邢卉春;王琦;李越;張斌;樊萬虎;袁菊;張黎穎;洪源;;應(yīng)用酵母雙雜交技術(shù)篩選與乙型肝炎病毒e抗原結(jié)合蛋白2結(jié)合的肝細(xì)胞蛋白編碼基因[J];解放軍醫(yī)學(xué)雜志;2008年07期

6 周智勇,郭亞兵,侯金林;拉米夫定聯(lián)合藥物療法治療乙型肝炎病毒感染的進(jìn)展[J];中國抗感染化療雜志;2002年04期

7 周智勇,侯金林,陳永鵬,馬春曦,駱抗先;胸腺肽治療及病毒定量與人乙型肝炎病毒酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸基序變異發(fā)生的關(guān)系[J];臨床薈萃;2003年10期

8 蘇海濱;胡瑾華;王慧芬;季偉;李捍衛(wèi);;胸腺肽α1、α干擾素和拉米夫定聯(lián)合治療HBV慢性攜帶者的臨床研究[J];臨床肝膽病雜志;2005年05期

9 文啟明;宋寧;;胸腺肽α1與干擾素α-1b治療慢性乙型肝炎的療效比較[J];臨床肝膽病雜志;2007年01期

10 張久聰;孫利;;胸腺肽α_1在慢性病毒性肝炎抗病毒治療中的應(yīng)用[J];實用藥物與臨床;2010年02期

，

本文編號：2462159